symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
RASP,0.0077,-58.472176,1218,5942945,0,0.0026-0.0499,-0.0033,"Rasna Therapeutics, Inc.",USD,0001582249,US7538881068,753888106,Other OTC,PNK,Biotechnology,https://www.rasna.com,"Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It focuses on developing small molecule drug candidates targeting NPM1 and LSD1, which are implicated in the disease progression of leukemia and lymphoma. The company is developing RASP-201 (LSD1), an enzyme that demethylates lysine side chain of histones; and RASP-301, an NPM1 gene that provides instructions for making nucleophosmin protein. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York.",Ms. Keeren  Shah,Healthcare,US,,646 396 4087,420 Lexington Avenue,New York,NY,10170,,0,https://financialmodelingprep.com/image-stock/RASP.png,2015-02-24,False,False,False,False,False
